Covant Therapeutics specializes in developing innovative therapeutics through the application of covalency, which allows for the precise modulation of protein function and fate. Their approach is grounded in the understanding that nature regulates protein behavior through post-translational modifications on specific amino acids. By emulating these biological processes, Covant targets these modifications with covalent small molecules, aiming to create first-and-best-in-class therapeutics for significant drug targets. The company leverages advanced capabilities in chemistry, quantitative proteomics, and deep learning to enhance their drug discovery efforts.

To maximize the success of their therapeutic candidates, Covant focuses on accessible and reactive protein sites within their native contexts, utilizing a proprietary Reactome Atlas that provides extensive sequence coverage for thousands of proteins. Their state-of-the-art mass spectrometry platform, combined with automation and deep learning algorithms, enables them to explore the "dark proteome" and expand the range of targetable proteins. Additionally, Covant employs a proprietary covalent library and structural sciences to develop molecules that can covalently modify amino acid side chains, thereby advancing their drug development programs.

United States

Our Mission is to treat diseases with first-and best-in-class covalent therapeutics for the most significant drug targets by leveraging our cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning.

Covant Therapeutics

Company Details